Sign In
Buy CTLT
$63.49
+0 (+0%)
At Close: Mar 14, 2025
Catalent (CTLT) Up 3.5% Since Last Earnings Report: Can It Continue?
12:34pm, Wednesday, 12'th Jul 2023
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Catalent's (CTLT) Facility Snag Linked to Regeneron's Eylea CRL
11:23am, Thursday, 29'th Jun 2023
Catalent's (CTLT) drug manufacturing facility in Indiana faces problems, which is linked to FDA's rejection of Regeneron's eye drug application. This is the latest in a string of quality control issue
Why Catalent Stock Flopped Today
06:40pm, Wednesday, 28'th Jun 2023
Difficulties at the contract manufacturer's site were apparently the reason for a drug's rejection by the FDA. That drug, a more potent form of eye medication Eylea, is made by biotech Regeneron Pharm
Catalent (CTLT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:32am, Tuesday, 13'th Jun 2023
Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street
Catalent, Inc. (CTLT) Q3 2023 Earnings Call Transcript
12:55pm, Monday, 12'th Jun 2023
Catalent, Inc. (NYSE:CTLT ) Q3 2023 Earnings Conference Call June 12, 2023 8:15 AM ET Company Participants Paul Surdez - Vice President, Investor Relations Alessandro Maselli - President and Chief Exe
Markets Gain Amid Anticipation of a Fed Rate Hike Pause
12:05pm, Monday, 12'th Jun 2023
U.S. equities were up at midday on Monday, June 12, 2023 amid optimism the Fed will pause its rate hike cycle.
Catalent (CTLT) Tops Q3 Earnings Estimates, Cuts FY23 View
11:58am, Monday, 12'th Jun 2023
Catalent (CTLT) records lower revenues in both segments in third-quarter fiscal 2023, resulting in overall soft performance.
Catalent shares rise as 3Q revenue beat overshadows revised outlook
11:16am, Monday, 12'th Jun 2023
Catalent shares rose by double digits on Monday after the contract drug maker reported a third-quarter fiscal 2023 revenue beat, despite swinging to a loss and slashing its fiscal 2023 outlook for sal
Catalent Cuts Outlook After Releasing Delayed Earnings. The Stock Rises.
10:15am, Monday, 12'th Jun 2023
Catalent reports an adjusted loss of 9 cents a share in its fiscal third quarter on revenue of $1.04 billion.
Catalent (CTLT) Reports Q3 Loss, Tops Revenue Estimates
09:28am, Monday, 12'th Jun 2023
Catalent (CTLT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to earnings of $1.04 per share a year ago.
Catalent, Inc. Announces Third Quarter Fiscal Year 2023 Earnings Conference Webcast
04:19pm, Friday, 09'th Jun 2023
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it will release financ
Catalent (CTLT) Launches Expanded OneBio Suite to Aid Customers
12:57pm, Friday, 09'th Jun 2023
Catalent's (CTLT) expansion of its OneBio Suite across multiple biologic therapies is expected to aid customers in leveraging its end-to-end capabilities in these areas.
Five Stocks Turn $10,000 To $44,175 In Five Months
08:00am, Wednesday, 31'st May 2023
May was only a so-so month for most S&P 500 investors. But some investors who hit the tech-stock boom just right this month did really well.
Catalent (CTLT) Expands Its Facility Capabilities in Shiga
12:40pm, Tuesday, 30'th May 2023
Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Supply Services network.
Why Catalent Stock Could Only Inch Higher Today
06:28pm, Monday, 22'nd May 2023
The specialty healthcare company gets another piece of bad news. But this was comparatively mild when judged against other recent developments.
